期刊文献+

5-氟尿嘧啶和多西紫杉醇稳态血药浓度影响化疗不良反应及近期疗效 被引量:12

Effects of Stability Plasma Concentration of 5-Fu and Docetaxel on Adverse Events and Short Term Effect after 5-Fu and Docetaxel Chemotherapy
在线阅读 下载PDF
导出
摘要 目的回顾性分析5-氟尿嘧啶(5-fluorouracil,5-Fu)和多西紫杉醇(Docetaxel,DOC)稳态血药浓度与联合化疗毒性反应和近期疗效的相关性。方法用5-Fu联合DOC方案(5-Fu 2.5 g/m2维持静脉滴注120 h,亚叶酸钙0.2 g,d1~5,DOC 75 mg/m2,d1,21天重复)化疗的胃癌或食管癌患者40例,采用高效液相色谱法分别测定化疗后5-Fu和DOC稳态血药浓度。采用Fisher精确概率法分析5-Fu和DOC稳态血药浓度和化疗不良反应及近期疗效的相关性。结果 5-Fu稳态血药浓度个体间变异较大,血药浓度范围为1.2~96.6 mg/L;DOC血药浓度范围为0.34~0.98 mg/L。按5-Fu血药浓度【30 mg/L和≥30 mg/L将患者分为两组,两组之间腹泻、黏膜炎严重程度差异有统计学意义,但近期疗效差异无统计学意义;按DOC血药浓度【4.9 mg/L和≥4.9 mg/L分为两组,高浓度组患者骨髓抑制程度及临床疗效均明显高于低浓度组。结论相同体表面积剂量下5-Fu和DOC联合化疗后稳态血药浓度个体间存在显著差异,稳态浓度影响了联合化疗后毒性反应的严重程度及近期疗效,提示进行血药浓度监测可以预测化疗毒性及疗效。 Objective To analyse the relationship between stability plasma concentration of 5-Fu, docetaxel and adverse effects, short term effect. Methods Forty patients with gastic cancer or esophageal caner received the same regimen(continuous infusion of 5-Fu 2.5g/m2for 120 h, leucovorin 200 mg d1-5 and paclitaxel 75mg /m2d1 every three weeks).The stability concentrations of 5-Fu and docetaxel were detected by high-performance liquid chromatography(HPLC).The relationship between stability plasma concentration of 5-Fu,docetaxel and adverse effects, short term effect was analysed with Fisher's exact test.Results The interindividual variation of 5-Fu stability plasma concentration was large.The concentration of 5-Fu varied from 1.2 mg/L to 99.6 mg/L,and docetaxel varied from 0.34 mg/L to 0.98 mg/L,which were demonstrated normalitydistribution.Patients were grouped in to two groups which were 5-Fu concentration <30 mg/L and ≥30 mg/L, the degree of diarrhea and mucositis had obvious difference between the two groups, while short term effect had no difference. When the two groups were divided by docetaxel concentration <4.9mg/L and ≥4.9 mg/L, patients with high concentration docetaxel had more severe myelosupression and better short term effect.Conclusion The stability concentration of 5-Fu and docetaxel had large interindividual variability after chemotherapy according to body surface area. The stability concentration effected the adverse events and short term effect. Mornitoring plasma concentration of chemotherapeutics may predict the toxicity and effect.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2014年第1期53-56,共4页 Cancer Research on Prevention and Treatment
基金 江西省卫生厅科技计划资助项目(20081009)
关键词 5-氟尿嘧啶 多西紫杉醇 血药浓度 不良反应 疗效 5-fluorouracil(5-Fu) Docetaxel Plasma concentration Adverse events Effect
  • 相关文献

参考文献11

  • 1张国伟,潘群雄,林志航,庄权权.HPLC法测定人血浆中多西他赛的浓度[J].中国药房,2012,23(14):1286-1288. 被引量:11
  • 2蔡讯,薛鹏,宋卫峰,胡炯,顾鸿莉,杨海燕,王理伟.氟尿嘧啶血药浓度监测在进一步提高晚期胃癌化疗疗效及减少不良反应预测中的作用[J].肿瘤,2011,31(10):930-936. 被引量:22
  • 3彭柔君,董秋美,史艳侠,曹烨,周中梅,袁中玉,李苏,廖海,姜文奇.胃癌患者外周血DPD活性、5-FU血药浓度与毒性反应的相关性分析[J].癌症,2006,25(8):1039-1043. 被引量:8
  • 4Marc Ychou,Jacqueline Duffour,Andrew Kramar,Charles Debrigode,Sophie Gourgou,Fran?oise Bressolle,Frédéric Pinguet.Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen[J]. Cancer Chemotherapy and Pharmacology . 2003 (4)
  • 5Di Paolo Antonello,Lencioni Monica,Amatori Federica,Di Donato Samantha,Bocci Guido,Orlandini Cinzia,Lastella Marianna,Federici Francesca,Iannopollo Mauro,Falcone Alfredo,Ricci Sergio,Del Tacca Mario,Danesi Romano.5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research . 2008
  • 6Akiko Kuwahara,Motohiro Yamamori,Kaori Kadoyama,Kohshi Nishiguchi,Tsutomu Nakamura,Ikuya Miki,Takao Tamura,Tatsuya Okuno,Hideaki Omatsu,Toshiyuki Sakaeda.Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Journal of Experimental & Clinical Cancer Research . 2011
  • 7Frederike K. Engels,Walter J. Loos,Jessica M. van der Bol,Peter de Bruijn,Ron H.J. Mathijssen,Jaap Verweij,Ron A.A. Math.Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study. Clinical Cancer Research . 2011
  • 8Saif M Wasif,Choma Adrienne,Salamone Salvatore J,Chu Edward.Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. Journal of the National Cancer Institute . 2009
  • 9AC Hooker,AJ Ten Tije,MA Carducci,J Weber,E Garrett-Mayer,H Gelderblom,WP Mcguire,J Verweij,MO Karlsson,SD Baker.Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements. Clinical Pharmacokinetics . 2008
  • 10Sharyn D. Baker,Ming Zhao,Carlton K. K. Lee,Jaap Verweij,Yelena Zabelina,Julie R. Brahmer,Antonio C. Wolff,Alex Sparreboom,Michael A. Carduc.Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel. Clinical Cancer Research . 2004

二级参考文献35

  • 1马韬,朱正纲,纪玉宝,张奕,刘炳亚,于颖彦,尹浩然,林言箴.氟尿嘧啶代谢酶与胃肠道肿瘤化疗敏感性关系的探讨[J].肿瘤,2004,24(6):558-561. 被引量:3
  • 2上海市肿瘤研究所流行病学研究室.1997年上海市市区恶性肿瘤发病率[J].肿瘤,2000,20(2):158-158.
  • 3PARKIN D M, BRAY F, FERLAY J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2): 74-108.
  • 4GAMELIN E C, DANQUECHIN-DORVAL E M, DUMESNIL Y F, et al. Relationship between 5-fluorouracil (5-FU) dose intensity andtherapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU[J]. Cancer, 1996, 77(3): 441-451.
  • 5VAN CUTSEM E, MOISEYENKO V M, TJULANDIN S, et al. Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin andfluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group[J].J Clin Oncol, 2006, 24(31 ): 4991-4997.
  • 6CUNNINGHAM D, STARLING N, RAO S, et al. Capecitabine and oxaliplatin for advancedesophagogastric cancer[J]. N Engl J Med, 2008, 358(1): 36-46.
  • 7KILICKAP S, YALCIN S, ATES O, et al. The first line systemic chemotherapy in metastatic gastric carcinoma: A comparison of docetaxel, cisplatinand fluorouracil (DCF) versus cisplatin and fluorouracil (CF); versus epirubicin, cisplatin and fluorouracil (ECF) regimens in clinical setting[J].Hepatogastroenterology, 2011, 58(105): 208-212.
  • 8GAMELIN E, DELVA R, JACOB J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared withconventional dosage: results of a multicenter randomized trial of patients with metastaticcolorectal cancer[J]. J Clin Oncol, 2008, 26(13): 2099-2105.
  • 9METZGER G, MASSARI C, ETIENNE M C, et al. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracilcoadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patientswith cancer[J]. Clin Pharmacol Ther, 1994, 56(2): 190-201.
  • 10EZZELDIN H, DIASIO R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration[J]. Clin Colorectal Cancer, 2004, 4(3): 181-189.

共引文献36

同被引文献99

  • 1岳凤洁.多西紫杉醇联合顺铂方案化疗对卵巢癌患者血糖的影响[J].医学信息,2017,30(25):73-74. 被引量:1
  • 2周志伟,王国强,万德森,潘志忠,李苏,陈功,廖海.二氢嘧啶脱氢酶活性与结直肠癌患者5-FU辅助化疗毒性关系的研究[J].癌症,2004,23(z1):1512-1516. 被引量:6
  • 3魏成明,晏军,王琳,欧海.血红蛋白水平对晚期胃癌化疗疗效及预后的影响[J].实用癌症杂志,2014,29(2):135-136. 被引量:7
  • 4毛茅,钱晓萍.免疫分析法在体内药物分析中的应用[J].海峡药学,2007,19(7):93-96. 被引量:5
  • 5Saam J, Critchfield GC, Hamilton SA, et al. Body surface area- based dosing of 5-fluorouracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens[J]. Clin Colorectal Cancer, 2011,10 (3) : 203-206.
  • 6Eisenhauer EA, Therasse P, Bogaerts J, et al. New response / evaluation criteria in solid tumours: revised RECIST guideline / (Version 1.1)[J]. Eur J Cancer,2009,45(2) :228-247.
  • 7Kaldate RR, Haregewoin A, Grier CE, et al. Modeling the 5-Fu area the curve versus dose relationship to develop a pharmacokinetics dosing algorithm for colorectal cancer patients receiving FOLFOX6[J]. Oncologist,2012,17(3) :296-302.
  • 8Gameline, Delva R, Jacob J, et al. Individual fluorouraeil dose adjustment based on pharrnacokinetie follow-up compared with conventional dosage: results of a multieenter randomized trial of patients with metastatic colorectai cancer[J]. J Clin Oneol, 2008,26 (13) : 2099-2105.
  • 9Capitain O, Asevoaia A, Boisdron-Celle M, et al. Individual fluorouraeil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body- area-surface dosing: a phase Ⅱ, proof-of-concept study[J]. Clin Coloreetal Cancer,2012,11(4) : 263-267.
  • 10HUR H, KANG J, KIM N K, et al. Thymidylate synthase gene po- ly - morphism affects the response to preoperative 5 - fluorouracil chemo- radiationtherapy in patients with rectal cancer [ J ]. Int J Radiat Oncol Biol Phys, 2011,81 ( 3 ) :669 - 676.

引证文献12

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部